JP2015520762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520762A5 JP2015520762A5 JP2015513209A JP2015513209A JP2015520762A5 JP 2015520762 A5 JP2015520762 A5 JP 2015520762A5 JP 2015513209 A JP2015513209 A JP 2015513209A JP 2015513209 A JP2015513209 A JP 2015513209A JP 2015520762 A5 JP2015520762 A5 JP 2015520762A5
- Authority
- JP
- Japan
- Prior art keywords
- pasireotide
- weight
- formulation
- component
- receptor agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 35
- 238000009472 formulation Methods 0.000 claims 22
- VMZMNAABQBOLAK-DBILLSOUSA-N pasireotide Chemical compound C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 VMZMNAABQBOLAK-DBILLSOUSA-N 0.000 claims 20
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 20
- 229960005415 pasireotide Drugs 0.000 claims 13
- 108700017947 pasireotide Proteins 0.000 claims 13
- 229940123051 Somatostatin receptor agonist Drugs 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 239000003963 antioxidant agent Substances 0.000 claims 7
- 230000003078 antioxidant effect Effects 0.000 claims 7
- 235000006708 antioxidants Nutrition 0.000 claims 7
- 150000001982 diacylglycerols Chemical class 0.000 claims 5
- 239000002798 polar solvent Substances 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 4
- HSXBEUMRBMAVDP-QKXVGOHISA-N [(3s,6s,9s,12r,15s,18s,20r)-9-(4-aminobutyl)-3-benzyl-12-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] n-(2-aminoethyl)carbamate;4-[(3-carboxy-2-hydroxynaphtha Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 HSXBEUMRBMAVDP-QKXVGOHISA-N 0.000 claims 4
- 229960002570 pasireotide pamoate Drugs 0.000 claims 4
- 206010000599 Acromegaly Diseases 0.000 claims 3
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 3
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 3
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- AFSHUZFNMVJNKX-UHFFFAOYSA-N 1,2-di-(9Z-octadecenoyl)glycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCC=CCCCCCCCC AFSHUZFNMVJNKX-UHFFFAOYSA-N 0.000 claims 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 2
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 claims 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 2
- RFVFQQWKPSOBED-PSXMRANNSA-N 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCC RFVFQQWKPSOBED-PSXMRANNSA-N 0.000 claims 2
- TYAQXZHDAGZOEO-KXQOOQHDSA-N 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCC TYAQXZHDAGZOEO-KXQOOQHDSA-N 0.000 claims 2
- MZWGYEJOZNRLQE-KXQOOQHDSA-N 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC MZWGYEJOZNRLQE-KXQOOQHDSA-N 0.000 claims 2
- ATHVAWFAEPLPPQ-VRDBWYNSSA-N 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC ATHVAWFAEPLPPQ-VRDBWYNSSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 208000014446 corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920002946 poly[2-(methacryloxy)ethyl phosphorylcholine] polymer Polymers 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000008279 Dumping Syndrome Diseases 0.000 claims 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- 108010016076 Octreotide Proteins 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 1
- 208000032395 Post gastric surgery syndrome Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000009311 VIPoma Diseases 0.000 claims 1
- WFKFNBBHVLMWQH-QKXVGOHISA-N acetic acid;[(3s,6s,9s,12r,15s,18s,20r)-9-(4-aminobutyl)-3-benzyl-12-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] n-(2-aminoethyl)carbamate Chemical compound CC(O)=O.C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 WFKFNBBHVLMWQH-QKXVGOHISA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims 1
- 239000003629 gastrointestinal hormone Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 239000004973 liquid crystal related substance Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 229960002700 octreotide Drugs 0.000 claims 1
- 201000011116 pancreatic cholera Diseases 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2012/059917 | 2012-05-25 | ||
| PCT/EP2012/059917 WO2012160213A1 (en) | 2011-05-25 | 2012-05-25 | Controlled release peptide formulations |
| US201261730613P | 2012-11-28 | 2012-11-28 | |
| US61/730,613 | 2012-11-28 | ||
| PCT/EP2013/060739 WO2013174978A1 (en) | 2012-05-25 | 2013-05-24 | Somatostatin receptor agonist formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520762A JP2015520762A (ja) | 2015-07-23 |
| JP2015520762A5 true JP2015520762A5 (enExample) | 2016-07-28 |
| JP6374380B2 JP6374380B2 (ja) | 2018-08-15 |
Family
ID=49623188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513209A Active JP6374380B2 (ja) | 2012-05-25 | 2013-05-24 | ソマトスタチン受容体作動薬製剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11672843B2 (enExample) |
| JP (1) | JP6374380B2 (enExample) |
| KR (1) | KR102139080B1 (enExample) |
| CN (1) | CN104487050B (enExample) |
| AU (1) | AU2013265210B2 (enExample) |
| BR (1) | BR112014029425A2 (enExample) |
| CA (1) | CA2874367C (enExample) |
| CL (1) | CL2014003185A1 (enExample) |
| CO (1) | CO7160067A2 (enExample) |
| DK (1) | DK2861209T3 (enExample) |
| EA (1) | EA035495B1 (enExample) |
| ES (1) | ES2834318T3 (enExample) |
| HK (1) | HK1207985A1 (enExample) |
| IL (1) | IL235740A0 (enExample) |
| IN (1) | IN2014DN09831A (enExample) |
| MA (1) | MA37672A1 (enExample) |
| MX (1) | MX350964B (enExample) |
| NZ (1) | NZ702028A (enExample) |
| PE (1) | PE20150195A1 (enExample) |
| PH (1) | PH12014502614A1 (enExample) |
| SG (1) | SG11201407678YA (enExample) |
| TN (1) | TN2014000483A1 (enExample) |
| WO (1) | WO2013174978A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1768650B1 (en) * | 2004-06-04 | 2008-07-16 | Camurus Ab | Liquid depot formulations |
| CN103702662B (zh) * | 2011-05-25 | 2018-07-20 | 卡穆鲁斯公司 | 控制释放肽制剂 |
| AU2017336199B2 (en) * | 2016-09-27 | 2020-08-20 | Camurus Ab | Mixtures and formulations comprising an alkyl ammonium EDTA salt |
| CN113018248B (zh) * | 2019-12-23 | 2022-07-22 | 南京清普生物科技有限公司 | 一种缓释递药系统 |
| CN114240934B (zh) * | 2022-02-21 | 2022-05-10 | 深圳大学 | 一种基于肢端肥大症的图像数据分析方法及系统 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5340802A (en) | 1989-06-30 | 1994-08-23 | Abbott Laboratories | Peptide analog type-B CCK receptor ligands |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| CA2535463A1 (en) | 1989-07-07 | 1991-01-08 | Novartis Ag | Octreotide-pamoate and its use in sustained release formulations of water soluble peptides |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| WO1993006921A1 (en) | 1991-10-04 | 1993-04-15 | Gs Biochem Ab | Particles, method of preparing said particles and uses thereof |
| CA2120359C (en) | 1991-10-04 | 2000-12-26 | Tomas Landh | Particles, method of preparing said particles and uses thereof |
| US6228383B1 (en) | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
| AU685262B2 (en) | 1994-03-30 | 1998-01-15 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
| SE518578C2 (sv) | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
| FR2725369B1 (fr) | 1994-10-07 | 1997-01-03 | Oreal | Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire |
| AU702030B2 (en) | 1995-10-12 | 1999-02-11 | Gs Development Ab | A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| EP0975331A1 (en) | 1997-04-17 | 2000-02-02 | Dumex-Alpharma A/S | A novel bioadhesive drug delivery system based on liquid crystals |
| US6638621B2 (en) | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
| US20040018241A1 (en) | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| BE1011899A6 (fr) | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| EP1600162A1 (en) | 1998-12-22 | 2005-11-30 | Eli Lilly & Company | Shelf-stable formulation of glucagon-like peptide-1 |
| US6011067A (en) | 1999-06-11 | 2000-01-04 | Thione International, Inc. | Antioxidant composition for the treatment of psoriasis and related diseases |
| GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| US20020153508A1 (en) | 2000-06-29 | 2002-10-24 | Lynch Matthew Lawrence | Cubic liquid crystalline compositions and methods for their preparation |
| US7008646B2 (en) | 2001-02-20 | 2006-03-07 | Patrick Thomas Spicer | Cubic liquid crystalline compositions and methods for their preparation |
| US6936187B2 (en) | 2001-02-21 | 2005-08-30 | Matthew Lawrence Lynch | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| US6656385B2 (en) | 2001-02-21 | 2003-12-02 | The Procter & Gamble Company | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| CA2451432A1 (en) | 2001-06-23 | 2003-01-03 | Lyotropic Therapeutics, Inc. | Particles with improved solubilization capacity |
| US20030119734A1 (en) | 2001-06-28 | 2003-06-26 | Flink James M. | Stable formulation of modified GLP-1 |
| AU2003201998C1 (en) | 2002-01-10 | 2012-10-25 | Imperial Innovations Limited | Modification of feeding behavior |
| US7622118B2 (en) | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| GB0305941D0 (en) | 2003-03-14 | 2003-04-23 | Camurus Ab | Composition |
| GB0307777D0 (en) | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
| WO2005014162A1 (en) | 2003-08-04 | 2005-02-17 | Camurus Ab | Method for improving the properties of amphiphile particles |
| EP1663295A2 (en) | 2003-09-01 | 2006-06-07 | Novo Nordisk A/S | Stable formulations of peptides |
| GB0322033D0 (en) | 2003-09-19 | 2003-10-22 | Camurus Ab | Composition |
| EP1682091B1 (en) | 2003-11-07 | 2017-03-29 | Camurus Ab | Compositions of lipids and cationic peptides |
| WO2005063213A1 (en) | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Rigid liposomal cochleate and methods of use and manufacture |
| EP1713446B1 (en) | 2004-01-23 | 2010-12-01 | Camurus Ab | Ternary non-lamellar lipid compositions |
| GB0401513D0 (en) | 2004-01-23 | 2004-02-25 | Camurus Ab | Compositions |
| EP1768650B1 (en) | 2004-06-04 | 2008-07-16 | Camurus Ab | Liquid depot formulations |
| JP5513713B2 (ja) | 2004-08-04 | 2014-06-04 | カムルス エービー | 非層状分散を生じる組成物 |
| WO2006075123A1 (en) | 2005-01-14 | 2006-07-20 | Camurus Ab | Topical bioadhesive formulations |
| PL1843746T3 (pl) | 2005-01-14 | 2011-09-30 | Camurus Ab | Formulacje analogów somatostatyny |
| KR100983746B1 (ko) * | 2005-01-14 | 2010-09-24 | 카무러스 에이비 | 소마토스타틴 유사 제형 |
| ES2343641T3 (es) * | 2005-01-14 | 2010-08-05 | Camurus Ab | Formulaciones bioadhesivas topicas. |
| WO2006077362A1 (en) * | 2005-01-21 | 2006-07-27 | Camurus Ab | Pharmaceutical lipid compositions |
| CN101217940B (zh) * | 2005-06-06 | 2013-03-27 | 卡穆鲁斯公司 | Glp-1类似物制剂 |
| US8097239B2 (en) | 2005-06-06 | 2012-01-17 | Camurus Ab | Controlled-release formulations |
| WO2007061896A1 (en) | 2005-11-17 | 2007-05-31 | Zogenix, Inc. | Delivery of viscous formulations by needle-free injection |
| GB0602639D0 (en) * | 2006-02-09 | 2006-03-22 | Novartis Ag | Organic compounds |
| PE20090387A1 (es) * | 2007-05-24 | 2009-04-28 | Novartis Ag | Formulacion de pasireotida |
| GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| ES2399651T3 (es) * | 2008-07-08 | 2013-04-02 | Novartis Ag | Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena |
| GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| CN103702662B (zh) * | 2011-05-25 | 2018-07-20 | 卡穆鲁斯公司 | 控制释放肽制剂 |
| CN104093399B (zh) * | 2011-12-05 | 2018-03-13 | 卡穆鲁斯公司 | 鲁棒性控释肽制剂 |
-
2013
- 2013-05-24 AU AU2013265210A patent/AU2013265210B2/en active Active
- 2013-05-24 CN CN201380034030.8A patent/CN104487050B/zh active Active
- 2013-05-24 CA CA2874367A patent/CA2874367C/en active Active
- 2013-05-24 SG SG11201407678YA patent/SG11201407678YA/en unknown
- 2013-05-24 IN IN9831DEN2014 patent/IN2014DN09831A/en unknown
- 2013-05-24 DK DK13724299.6T patent/DK2861209T3/da active
- 2013-05-24 MA MA37672A patent/MA37672A1/fr unknown
- 2013-05-24 NZ NZ702028A patent/NZ702028A/en not_active IP Right Cessation
- 2013-05-24 WO PCT/EP2013/060739 patent/WO2013174978A1/en not_active Ceased
- 2013-05-24 BR BR112014029425A patent/BR112014029425A2/pt not_active Application Discontinuation
- 2013-05-24 HK HK15108712.3A patent/HK1207985A1/xx unknown
- 2013-05-24 KR KR1020147036398A patent/KR102139080B1/ko active Active
- 2013-05-24 ES ES13724299T patent/ES2834318T3/es active Active
- 2013-05-24 JP JP2015513209A patent/JP6374380B2/ja active Active
- 2013-05-24 MX MX2014014379A patent/MX350964B/es active IP Right Grant
- 2013-05-24 US US14/401,559 patent/US11672843B2/en active Active
- 2013-05-24 EA EA201491928A patent/EA035495B1/ru not_active IP Right Cessation
- 2013-05-24 PE PE2014002215A patent/PE20150195A1/es not_active Application Discontinuation
-
2014
- 2014-11-17 IL IL235740A patent/IL235740A0/en unknown
- 2014-11-21 TN TN2014000483A patent/TN2014000483A1/fr unknown
- 2014-11-24 CL CL2014003185A patent/CL2014003185A1/es unknown
- 2014-11-24 PH PH12014502614A patent/PH12014502614A1/en unknown
- 2014-12-18 CO CO14278535A patent/CO7160067A2/es unknown
-
2023
- 2023-04-26 US US18/307,124 patent/US20230372436A1/en not_active Abandoned
-
2025
- 2025-01-17 US US19/028,330 patent/US20260000730A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240781T1 (hr) | Formulacije peptida s kontroliranim oslobađanjem | |
| AR088458A1 (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod | |
| RU2020109881A (ru) | Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита | |
| JP2017519018A5 (enExample) | ||
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| HRP20200889T1 (hr) | Upotreba dugodjelujućih peptida glp-1 | |
| JP2015512392A5 (enExample) | ||
| HRP20161500T1 (hr) | Formulacije cikličkog somatostatina s polaganim otpuštanjem | |
| RU2016101064A (ru) | Состав с постоянным соотношением инсулина гларгина/ликсизенатида | |
| JP2008521840A5 (enExample) | ||
| US12097179B2 (en) | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof | |
| JP2020522502A5 (enExample) | ||
| Giustina et al. | Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors | |
| JP2022097600A (ja) | 抗ＴＮＦα抗体の液状製剤 | |
| CN105919998A (zh) | 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂 | |
| NZ225340A (en) | Pharmaceutical compositions comprising somatostatin analogues and lactic acid | |
| HRP20250009T1 (hr) | Čvrsta formulacija | |
| RU2017132330A (ru) | Соли производного хиназолина и способ их получения | |
| KR20220170782A (ko) | 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물 | |
| CA2594711A1 (en) | Somatostatin analogue formulations | |
| RU2008136073A (ru) | Комбинация аналогов соматостатина с различной селективностью в отношении подтипов рецепторов соматостатина человека | |
| Bush et al. | Management of acromegaly: is there a role for primary medical therapy? | |
| JP2020527574A5 (enExample) | ||
| JP6374380B2 (ja) | ソマトスタチン受容体作動薬製剤 | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo |